AIM ImmunoTech Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with NYSE American on November 12, 2026, reporting a net loss of $3.143 million for the third quarter and a significant increase in shares outstanding driven by stock issuances, warrant exercises, and debt repayments.

Key Highlights

  • Net loss of $3.143 million for the three months ended September 30, 2026, compared to a net loss of $3.284 million in the same period of 2025, according to the filing.
  • Total revenues of $22 thousand for Q3 2026, down from $26 thousand in Q3 2025, all attributed to clinical treatment programs in the U.S.
  • Cash and cash equivalents of $6.887 million as of September 30, 2026, up from $2.985 million at December 31, 2025.
  • Total assets of $9.751 million as of September 30, 2026, compared to $5.782 million at December 31, 2025.
  • Shares outstanding rose to 39,894,844 as of September 30, 2026, from 3,069,875 at December 31, 2025, reflecting multiple issuance events during the nine-month period.
  • Accumulated deficit of $450.740 million as of September 30, 2026, versus $440.786 million at December 31, 2025.
  • Stockholders' equity turned positive at $7.076 million as of September 30, 2026, compared to a deficit of $9.783 million at December 31, 2025.

AIM ImmunoTech Reports Q3 2026 Financials: Loss Narrows, Capital Position Strengthens

According to the filing, AIM ImmunoTech Inc. (NYSE American:AIM) reported total revenues of $22 thousand for the three months ended September 30, 2026, entirely from U.S. clinical treatment programs. Total costs and expenses for the same quarter were $2.979 million, resulting in an operating loss of $2.957 million. For the nine months ended September 30, 2026, the company disclosed total revenues of $70 thousand and an operating loss of $8.696 million, compared to an operating loss of $8.712 million in the nine months ended September 30, 2025.

The filing shows that the company's balance sheet shifted materially during the nine-month period. Total liabilities fell to $2.675 million as of September 30, 2026, from $15.565 million at December 31, 2025. The warrant liability, which stood at $8.244 million at year-end 2025, was reported as zero at September 30, 2026, following a reclassification of Warrants E and F that added $8.712 million to additional paid-in capital. Net cash used in operating activities for the nine months ended September 30, 2026, was $10.240 million, according to the cash flow statement.

The company's common share count expanded substantially during the nine-month period through several mechanisms disclosed in the statements of changes in stockholders' equity: a registered direct offering that raised net proceeds of $5.094 million, warrant exercises, conversions of Series G Convertible Preferred Stock to common stock, and repayment of debt with shares. As of September 30, 2026, 521 shares of Series G Convertible Preferred Stock remained issued and outstanding, with 12,000 shares authorized. The filing states that 39,919,844 shares of common stock were outstanding as of November 11, 2026.

What Was Disclosed

AIM ImmunoTech filed a quarterly report covering the period ended September 30, 2026, disclosing a net loss of $3.143 million for Q3 2026, a nine-month net loss of $9.954 million, an increase in cash to $6.887 million, and a shift from a stockholders' deficit to positive equity of $7.076 million.